Affiliations 

  • 1 School of Postgraduate Studies and Research, International Medical University, Bukit Jalil, Malaysia
  • 2 Department of Pharmacology, Faculty of Medicine, Mahsa University, Jenjarom, Malaysia
  • 3 Department of Pharmaceutical Chemistry, School of Pharmacy, International Medical University, Bukit Jalil, Malaysia
Expert Opin Drug Discov, 2022 Jan;17(1):79-92.
PMID: 34553659 DOI: 10.1080/17460441.2022.1985108

Abstract

INTRODUCTION: Artificial intelligence (AI) in drug discovery and development (DDD) has gained more traction in the past few years. Many scientific reviews have already been made available in this area. Thus, in this review, the authors have focused on the success stories of AI-driven drug candidates and the scientometric analysis of the literature in this field.

AREA COVERED: The authors explore the literature to compile the success stories of AI-driven drug candidates that are currently being assessed in clinical trials or have investigational new drug (IND) status. The authors also provide the reader with their expert perspectives for future developments and their opinions on the field.

EXPERT OPINION: Partnerships between AI companies and the pharma industry are booming. The early signs of the impact of AI on DDD are encouraging, and the pharma industry is hoping for breakthroughs. AI can be a promising technology to unveil the greatest successes, but it has yet to be proven as AI is still at the embryonic stage.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.